Monday, August 31, 2026

NeuroMetrix Stock Over 15% Down In The Last 5 Sessions

NeuroMetrix Stock Over 15% Down In The Last 5 Sessions

(VIANEWS) - Shares of NeuroMetrix (NASDAQ: NURO) fell by a staggering 15.47% in 5 sessions from $1.81 to $1.53 at 14:24 EST on Friday, after two sequential sessions in a row of losses. NASDAQ is sliding 1.26% to $11,196.00, following the last session's downward trend.

NeuroMetrix's last close was $1.63, 72.33% below its 52-week high of $5.89.

About NeuroMetrix

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.42.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -20.47%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.7%, now sitting on 8.23M for the twelve trailing months.

Moving Average

NeuroMetrix's value is way under its 50-day moving average of $1.71 and way under its 200-day moving average of $2.63.

Volatility

NeuroMetrix's last week, last month's, and last quarter's current intraday variation average was a positive 0.89%, a negative 0.19%, and a positive 2.68%.

NeuroMetrix's highest amplitude of average volatility was 1.44% (last week), 2.46% (last month), and 2.68% (last quarter).

Yearly Top and Bottom Value

NeuroMetrix's stock is valued at $1.53 at 14:24 EST, way below its 52-week high of $5.89 and way higher than its 52-week low of $1.33.

More news about NeuroMetrix (NURO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com